Clinical trial
Randomized, Controlled, Open-label, Double-blind, Multicenter Investigation Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.
NCT06214819 is registered in ClinicalTrials.gov with Fundación EPIC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Controlled, Open-label, Double-blind, Multicenter Investigation Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.
- Lead sponsor
- Fundación EPIC
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- March 20, 2024
- Completion date
- August 31, 2026
- Enrollment
- 40 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.